Stay updated on Efgartigimod SubQ in Idiopathic Inflammatory Myopathy Clinical Trial

Sign up to get notified when there's something new on the Efgartigimod SubQ in Idiopathic Inflammatory Myopathy Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Efgartigimod SubQ in Idiopathic Inflammatory Myopathy Clinical Trial page

  1. Check
    6 days ago
    No Change Detected
  2. Check
    13 days ago
    Change Detected
    Summary
    New study sites were added, including Universitaetsklinikum Hamburg-Eppendorf (Hamburg, Germany), Sichuan Provincial Academy of Medical Sciences and Sichuan Provincial People’s Hospital (Chengdu, China), Peking Union Medical College Hospital (Beijing, China), Multiprofile hospital for active treatment Kaspela EOOD (Plovdiv, Bulgaria), and University of North Carolina School of Medicine (Chapel Hill, NC). The total number of locations is now 78.
    Difference
    0.9%
    Check dated 2026-02-11T12:47:19.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    A general funding-status notice was added and the page shows revision v3.4.1, replacing v3.4.0.
    Difference
    0.3%
    Check dated 2026-02-04T07:54:24.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    New UI element added: a Show glossary option, and several metadata fields were updated or renamed (Last Update Submitted that Met QC Criteria, Last Update Posted, No FEAR Act Data) with a revision bump from v3.3.4 to v3.4.0; to avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.2%
    Check dated 2026-01-28T05:41:02.000Z thumbnail image
  5. Check
    42 days ago
    Change Detected
    Summary
    Added four new study sites: Chukyo Hospital in Nagoya, Juntendo University Hospital in Bunkyō City, Ospedale Sant’Andrea in Rome, and University College Dublin / SVUH in Dublin, and updated the total number of locations to 73.
    Difference
    0.5%
    Check dated 2026-01-14T02:50:13.000Z thumbnail image
  6. Check
    63 days ago
    Change Detected
    Summary
    A new consolidated Locations section lists recruitment sites by state, replacing prior separate state location entries. This clarifies where the study is enrolling and expands access for potential participants.
    Difference
    0.8%
    Check dated 2025-12-23T17:32:56.000Z thumbnail image
  7. Check
    78 days ago
    Change Detected
    Summary
    Added comprehensive study details including the Efgartigimod PH20 SC treatment plan (up to 51 months) and long-term safety/tolerability endpoints. Expanded site list to 69 locations worldwide and updated timelines, enrollment, and eligibility criteria.
    Difference
    4%
    Check dated 2025-12-09T01:08:58.000Z thumbnail image

Stay in the know with updates to Efgartigimod SubQ in Idiopathic Inflammatory Myopathy Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Efgartigimod SubQ in Idiopathic Inflammatory Myopathy Clinical Trial page.